Understanding Tysabri and Progressive Multifocal Leukoencephalopathy (PML)
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Awareness to Specific Legal Considerations
If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection is a known complication of the medication. The medical community has long recognized the importance of balancing therapeutic benefits with potential risks, and this page provides an objective overview of Tysabri-associated PML, including symptoms and monitoring strategies.
Medical Background and Risk Factors for Tysabri-Associated PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations for filing a claim—is critical. PML is an opportunistic viral infection of the brain caused by the JC virus that typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, weighing expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Clinical Presentation, Diagnosis, and Mechanistic Pathways
PML typically presents with progressive neurological deficits such as weakness, cognitive decline, visual disturbances, or speech difficulties. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The prescribing information emphasizes that healthcare professionals should monitor patients on Tysabri for any new sign or symptom suggestive of PML and that dosing should be withheld immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because PML can progress rapidly, early recognition is essential. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance, allowing JC virus reactivation and uncontrolled replication in the brain. The resulting lytic infection of oligodendrocytes leads to demyelination and neuronal damage, causing the clinical syndrome of PML.
Adequacy of Warnings and Settlement Considerations
The FDA-approved labeling includes a boxed warning that clearly states the PML risk and identifies known risk factors. However, the adequacy of these warnings in practice may be questioned. For example, the warning advises that risk factors should be considered when initiating and continuing treatment, but it does not provide quantitative risk estimates for individual patients. Additionally, the TOUCH Prescribing Program requires patient enrollment and education about risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), yet some patients may not fully understand the implications. In legal contexts, plaintiffs may argue that warnings were insufficient to convey the severity or likelihood of PML, particularly for patients with multiple risk factors. Patients in Virginia who have developed PML after Tysabri use may be eligible for compensation through settlements or litigation. Key considerations include the timeline between exposure and documented harm. PML can occur after varying durations of Tysabri treatment, from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The statute of limitations for filing a claim in Virginia is generally two years from the date the injury was discovered or reasonably should have been discovered. This means that patients or their families must act promptly after a PML diagnosis to preserve legal rights. Settlement amounts may depend on factors such as severity of disability, medical expenses, lost income, and evidence of inadequate warnings.
Timeline Between Exposure and Harm: Implications for Virginia Patients
The prescribing information notes that PML risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported after shorter exposure. The latency period between starting Tysabri and PML onset can be months to years, complicating the determination of when the injury occurred for statute of limitations purposes. Virginia courts typically apply the 'discovery rule,' meaning the clock starts when the patient knew or should have known that PML was caused by Tysabri. Medical records documenting the diagnosis and its link to the drug are crucial. For Virginia patients affected by Tysabri-associated PML, the medical evidence clearly establishes a causal link through known risk factors and mechanistic pathways. The adequacy of warnings remains a potential legal issue, and the statute of limitations requires timely action. Patients should consult with a qualified attorney experienced in pharmaceutical litigation to evaluate their specific circumstances and ensure compliance with Virginia's filing deadlines.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in Virginia?
In Virginia, the statute of limitations for personal injury claims, including those related to Tysabri-associated PML, is generally two years from the date the injury was discovered or reasonably should have been discovered. This means that patients or their families must file a lawsuit within two years of the PML diagnosis or when they became aware that Tysabri caused the injury. It is crucial to act promptly to preserve legal rights.
What are the risk factors for developing PML while on Tysabri?
Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, weighing expected benefit against PML risk.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.